CN108218873B - 流感病毒复制抑制剂及其用途 - Google Patents

流感病毒复制抑制剂及其用途 Download PDF

Info

Publication number
CN108218873B
CN108218873B CN201711361166.6A CN201711361166A CN108218873B CN 108218873 B CN108218873 B CN 108218873B CN 201711361166 A CN201711361166 A CN 201711361166A CN 108218873 B CN108218873 B CN 108218873B
Authority
CN
China
Prior art keywords
atoms
alkylene
group
compound
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711361166.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108218873A (zh
Inventor
唐昌华
任青云
殷俊俊
易凯
雷义波
王叶俊
张英俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN108218873A publication Critical patent/CN108218873A/zh
Application granted granted Critical
Publication of CN108218873B publication Critical patent/CN108218873B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201711361166.6A 2016-12-15 2017-12-14 流感病毒复制抑制剂及其用途 Active CN108218873B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611158754 2016-12-15
CN2016111587545 2016-12-15

Publications (2)

Publication Number Publication Date
CN108218873A CN108218873A (zh) 2018-06-29
CN108218873B true CN108218873B (zh) 2020-07-07

Family

ID=62558051

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711361166.6A Active CN108218873B (zh) 2016-12-15 2017-12-14 流感病毒复制抑制剂及其用途

Country Status (8)

Country Link
US (1) US10987354B2 (https=)
EP (1) EP3555095B1 (https=)
JP (1) JP7034162B2 (https=)
KR (1) KR102554019B1 (https=)
CN (1) CN108218873B (https=)
AU (1) AU2017376541B2 (https=)
CA (1) CA3045371C (https=)
WO (1) WO2018108125A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201804348SA (en) 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
CN108276401B (zh) 2017-01-05 2020-12-22 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2018157830A1 (en) 2017-03-02 2018-09-07 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN109384783A (zh) * 2017-08-09 2019-02-26 银杏树药业(苏州)有限公司 新型杂环化合物及其作为抗流感病毒抑制剂的医药用途
CN111665297B (zh) * 2019-03-05 2024-04-26 广东东阳光药业股份有限公司 一种Baloxavir marboxil光学异构体的分离检测方法
CN110013483B (zh) * 2019-05-10 2022-04-15 江苏师范大学 噻唑并[3,2-a]嘧啶-6-甲腈衍生物用于抗菌的用途
CN110305091B (zh) * 2019-06-19 2021-05-18 江苏理工学院 一种巴洛沙韦中间体化合物的制备方法
CN114340614B (zh) * 2019-09-27 2024-01-16 广东东阳光药业股份有限公司 一种奥司他韦制剂
CN112684028B (zh) * 2020-12-04 2022-05-17 中山奕安泰医药科技有限公司 一种2-(2-氯-1-亚乙基)酰肼甲酸甲酯纯度的检测方法
CN113603693B (zh) * 2021-07-13 2022-08-26 陕西丽彩药业有限公司 一种2-溴-5-对甲苯磺酰基-5H-吡咯并[2,3-b]吡嗪的制备方法
WO2026016541A1 (zh) * 2024-07-16 2026-01-22 武汉武药科技有限公司 一种新型抗病毒化合物及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006058120A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
LT3141252T (lt) 2009-06-17 2018-11-12 Vertex Pharmaceuticals Inc. Gripo virusų replikacijos inhibitoriai
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
CN103562205A (zh) 2010-12-16 2014-02-05 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
CA2822059A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2858984A1 (en) * 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
EP3068434A1 (en) * 2013-11-13 2016-09-21 Vertex Pharmaceuticals Inc. Formulations of azaindole compounds
JP6618901B2 (ja) 2013-11-13 2019-12-11 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
CN106573920B (zh) 2014-08-08 2020-11-10 爱尔兰詹森科学公司 用于在流感病毒感染中使用的吲哚
ES2860688T3 (es) 2014-09-08 2021-10-05 Janssen Sciences Ireland Uc Pirrolopirimidinas para uso en la infección por el virus de la gripe
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
JP6903658B2 (ja) 2015-11-27 2021-07-14 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー インフルエンザウィルス感染に使用するための複素環インドール
SG11201804225PA (en) 2015-12-09 2018-06-28 Sunshine Lake Pharma Co Ltd Inhibitors of influenza virus replication, application methods and uses thereof
DK3400225T3 (da) 2016-01-07 2022-01-03 Janssen Sciences Ireland Unlimited Co Pentansyrederivater substitueret med pyrrolo-[2,3-b]pyrimidinpyridiner til behandling af influenzavirusinfektioner
MX381314B (es) 2016-01-20 2025-03-12 Janssen Sciences Ireland Uc Pirimidinas sustituidas con arilo para su uso en la infeccion por virus influenza
WO2017133667A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017133658A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh 4, 7-diazaindole and 4, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza
WO2017133665A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh 6,7-diazaindazole and 6,7-diazaindole derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017133670A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133657A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133664A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment, amelioration or prevention of influenza
WO2017133669A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh 5, 7-diazaindole and 5, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza
WO2017198122A1 (zh) 2016-05-19 2017-11-23 四川大学 抗流感小分子化合物及其制备方法和用途
WO2018033082A1 (en) 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2018041091A1 (en) 2016-08-30 2018-03-08 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
RU2727772C1 (ru) 2016-09-05 2020-07-23 Гуандун Рэйновент Байотек Ко., Лтд. Производные пиримидина против вируса гриппа

Also Published As

Publication number Publication date
US10987354B2 (en) 2021-04-27
AU2017376541A1 (en) 2019-06-13
CN108218873A (zh) 2018-06-29
WO2018108125A1 (en) 2018-06-21
JP7034162B2 (ja) 2022-03-11
EP3555095B1 (en) 2023-04-12
EP3555095A1 (en) 2019-10-23
KR20190092545A (ko) 2019-08-07
CA3045371C (en) 2024-05-14
US20200085822A1 (en) 2020-03-19
CA3045371A1 (en) 2018-06-21
AU2017376541B2 (en) 2021-08-05
EP3555095A4 (en) 2020-07-01
JP2020513415A (ja) 2020-05-14
KR102554019B1 (ko) 2023-07-11

Similar Documents

Publication Publication Date Title
CN106854205B (zh) 流感病毒复制抑制剂及其使用方法和用途
CN108218873B (zh) 流感病毒复制抑制剂及其用途
CN109641868B (zh) 流感病毒复制抑制剂及其使用方法和用途
CN108276401B (zh) 流感病毒复制抑制剂及其用途
CN107759571B (zh) 流感病毒复制抑制剂及其使用方法和用途
TWI785116B (zh) 流感病毒複製抑制劑及其用途
CN110446711B (zh) 流感病毒复制抑制剂及其用途
CN110117285B (zh) 流感病毒复制抑制剂及其用途
CN110964023B (zh) 稠合四环类化合物及其在药物中的应用
CN113614085B (zh) 流感病毒复制抑制剂及其用途
HK1245776B (zh) 流感病毒复制抑制剂及其使用方法和用途
HK1252416B (zh) 流感病毒复制抑制剂及其用途
HK40002434A (en) Inhibitors of influenza virus replication, application methods and uses thereof
HK40002434B (zh) 流感病毒复制抑制剂及其使用方法和用途
HK40011746B (en) Inhibitors of influenza virus replication and uses thereof
HK40011746A (en) Inhibitors of influenza virus replication and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.

CP03 Change of name, title or address